Harpoon Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Corporate Update
Harpoon Therapeutics (NASDAQ: HARP), a clinical-stage immunotherapy company, will report its fourth quarter and full year 2020 financial results on March 10, 2021. This will be accompanied by a corporate update. The management will host a webcast and conference call at 4:30 p.m. ET/1:30 p.m. PT. Investors can access the call by dialing 866-951-6894 domestically or 409-216-0624 internationally. Harpoon is developing a novel class of T cell engagers for cancer treatment, with various products in clinical trials.
- Harpoon is advancing multiple clinical trials for its T cell engagers targeting cancers.
- HPN424, HPN536, HPN217, and HPN328 are in Phase 1/2 trials for significant cancer indications.
- No financial results are disclosed, leading to uncertainty about revenue and earnings.
- No updates on clinical trial progress or results, leaving potential investors without key performance indicators.
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will report fourth quarter and full year 2020 financial results and provide a corporate update on Wednesday, March 10, 2021. Harpoon’s management will host a webcast and conference call that day at 4:30 p.m. ET / 1:30 p.m. PT.
The live call may be accessed by dialing 866-951-6894 for domestic callers and 409-216-0624 for international callers and entering the conference code: 4785099. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.harpoontx.com.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon’s first ProTriTAC product candidate, HPN601, targets tumor antigen epithelial cell adhesion molecule (EpCAM), for the treatment of solid tumors and is currently in preclinical studies. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Contacts:
Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
media@harpoontx.com
Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com
FAQ
When will Harpoon Therapeutics report its financial results for 2020?
What time is the Harpoon Therapeutics conference call?
What is the latest on Harpoon Therapeutics' clinical trials?
How can I access the webcast for Harpoon's financial results?
